%0 Journal Article
%T EGFR-TKI治疗EGFR敏感突变的晚期肺鳞癌的疗效分析
%A 刘咏梅
%A 卢铀
%A 唐源
%A 张衍
%A 李艳莹
%A 王永生
%A 赵倩
%J 肿瘤防治研究
%D 2015
%R 10.3971/j.issn.1000-8578.2015.09.011
%X 摘要 目的 探讨表皮生长因子酪氨酸激酶抑制剂（Epidermal growth factor receptor-tyrosine kinase inhibitor, EGFR-TKI）治疗EGFR敏感突变的晚期肺鳞癌患者的疗效。方法 收集20例四川大学华西医院经病理确诊、EGFR检测敏感突变、并接受EGFR-TKI治疗的Ⅳ期或术后复发转移肺鳞癌患者，分析其与EGFR-TKI的疗效关系。结果 20例EGFR敏感突变的晚期鳞癌患者接受EGFR-TKI治疗，随访资料完整。10例19-del（+），8例L858R（+），1例同时存在外显子21（L858R）点突变和外显子20（T790M）突变，1例外显子18（G719X）突变。其中部分缓解（PR）9例，疾病稳定（SD）7例，疾病进展（PD）4例。客观缓解率（ORR）45%，疾病控制率80%，中位无进展生存期（mPFS）为5.0月，中位生存期（mOS）为14.7月。结论 EGFR-TKI对部分EGFR敏感突变的鳞癌患者有一定疗效。在临床工作中，应重视这部分患者的EGFR基因检测，以便明确获益的患者
%K 肺鳞癌
%K EGFR突变
%K EGFR-TKI
%K Advances of FGF/FGFR Signaling Pathway in Targeted Therapy for Squamous Cell Lung Cancer
%K Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer
%K Expression and Significance of NapsinA
%K TTF-1
%K CK5/6
%K CK7 and P63 in Biopsy Specimen by Bronchoscope of Non-small Cell Lung Cancer
%K Clinical Significance of Cyfra21-1 Analysis Combined with SELDI-TOF-MS Technology in Lung Squamous Carcinoma
%K Expression and Clinical Significance of Annexin-1 in Lung Squamous Carcinoma Tissues
%K RNA Interference-mediated Significant Enhancement of Apoptosis in Yunnan Gejiu Lung Squamous Carcinoma Cells(YTMLC) by siRNA Expression Vector Targeting Survivin Gene
%K The Expression and Clinical Significance of p53 and Prol iferating Cell Nuclear Antigen (PCNA) in Lung Squamous Cell Carcinoma
%K The Value of Free Sailic Acid(FSA)Determination in Lung Cancer Diagnosis
%U http://www.zlfzyj.com/CN/abstract/abstract8589.shtml